Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sorafenib Tosylate

FDA-approved product (tablet, oral), marketed as Nexavar, Sorafenib Tosylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sorafenib Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sorafenib Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sorafenib Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

    NCT03563170 · start 2018-05-25

    Registered record
    Registry ID
    NCT03563170
    Conditions
    Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent
    Interventions
    ETBX-011; GI-4000; haNK for infusion; avelumab; Capecitabine; Cyclophosphamide; 5-Fluorouracil; Leucovorin; nab-Paclitaxel; Sorafenib; SBRT; Aldoxorubicin hydrochloride; ETBX-051; ETBX-061; GI-6207; GI-6301; Cetuximab; N-803
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-05-25
    Completion
    2019-08-23
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent
    InterventionETBX-011; GI-4000; haNK for infusion; avelumab +14 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

    NCT03211416 · start 2017-12-07

    Registered record
    Registry ID
    NCT03211416
    Conditions
    Advanced Adult Hepatocellular Carcinoma; Child-Pugh Class A; Stage III Hepatocellular Carcinoma; Stage IIIA Hepatocellular Carcinoma; Stage IIIB Hepatocellular Carcinoma; Stage IIIC Hepatocellular Carcinoma; Stage IV Hepatocellular Carcinoma; Stage IVA Hepatocellular Carcinoma; Stage IVB Hepatocellular Carcinoma
    Interventions
    Laboratory Biomarker Analysis; Pembrolizumab; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-12-07
    Completion
    2025-08-15
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Adult Hepatocellular Carcinoma; Child-Pugh Class A; Stage III Hepatocellular Carcinoma; Stage IIIA Hepatocellular Carcinoma +5 more
    InterventionLaboratory Biomarker Analysis; Pembrolizumab; Sorafenib Tosylate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    NCT02270788 · start 2015-04-02

    Registered record
    Registry ID
    NCT02270788
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Crenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04-02
    Completion
    2016-10-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCrenolanib; Sorafenib; methotrexate, hydrocortisone and cytarabine with leucovorin
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

    NCT02050919 · start 2013-12-03

    Registered record
    Registry ID
    NCT02050919
    Conditions
    Pleomorphic Rhabdomyosarcoma; Stage IIB Adult Soft Tissue Sarcoma AJCC v7; Stage III Adult Soft Tissue Sarcoma AJCC v7; Stage IV Adult Soft Tissue Sarcoma AJCC v7
    Interventions
    Epirubicin Hydrochloride; External Beam Radiation Therapy; Ifosfamide; Laboratory Biomarker Analysis; Sorafenib Tosylate; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12-03
    Completion
    2020-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPleomorphic Rhabdomyosarcoma; Stage IIB Adult Soft Tissue Sarcoma AJCC v7; Stage III Adult Soft Tissue Sarcoma AJCC v7; Stage IV Adult Soft Tissue Sarcoma AJCC v7
    InterventionEpirubicin Hydrochloride; External Beam Radiation Therapy; Ifosfamide; Laboratory Biomarker Analysis +2 more
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

    NCT01817751 · start 2013-04-11

    Registered record
    Registry ID
    NCT01817751
    Conditions
    Glioblastoma; Recurrent Adult Brain Neoplasm; Malignant Glioma; WHO Grade III Glioma
    Interventions
    sorafenib tosylate; valproic acid; sildenafil citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04-11
    Completion
    2023-05-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Adult Brain Neoplasm; Malignant Glioma; WHO Grade III Glioma
    Interventionsorafenib tosylate; valproic acid; sildenafil citrate
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

    NCT01730937 · start 2013-04

    Registered record
    Registry ID
    NCT01730937
    Conditions
    Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
    Interventions
    Sorafenib; stereotactic body radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-04
    Completion
    2025-09-04
    Enrolment
    193

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
    InterventionSorafenib; stereotactic body radiation therapy
    PhasePhase 3
    Registry statusCompleted

  • Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

    NCT01664182 · start 2012-08-01

    Registered record
    Registry ID
    NCT01664182
    Conditions
    Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Bevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate; Trebananib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2020-12-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionBevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate +1 more
    PhasePhase 2
    Registry statusCompleted

  • Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

    NCT01576185 · start 2012-05

    Registered record
    Registry ID
    NCT01576185
    Conditions
    Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
    Interventions
    laboratory biomarker analysis; quizartinib; sorafenib tosylate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-05
    Completion
    2016-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Acute Myeloid Leukemia/Other Myeloid Malignancies
    Interventionlaboratory biomarker analysis; quizartinib; sorafenib tosylate
    PhaseNot recorded
    Registry statusCompleted

  • Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

    NCT01578109 · start 2012-01-13

    Registered record
    Registry ID
    NCT01578109
    Conditions
    Acute Myeloid Leukemia With FLT3/ITD Mutation
    Interventions
    Bone Marrow Transplantation; Sorafenib; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01-13
    Completion
    2021-03-07
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With FLT3/ITD Mutation
    InterventionBone Marrow Transplantation; Sorafenib; Sorafenib Tosylate
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

    NCT01502410 · start 2012-01

    Registered record
    Registry ID
    NCT01502410
    Conditions
    Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
    Interventions
    sorafenib tosylate; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer +3 more
    Interventionsorafenib tosylate; pharmacological study; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

    NCT01383343 · start 2011-08

    Registered record
    Registry ID
    NCT01383343
    Conditions
    Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
    Interventions
    Bevacizumab; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2017-02
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer +2 more
    InterventionBevacizumab; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium +1 more
    PhasePhase 1
    Registry statusCompleted

  • Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    NCT01371981 · start 2011-07-06

    Registered record
    Registry ID
    NCT01371981
    Conditions
    Acute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm; Myeloid Sarcoma
    Interventions
    Asparaginase; Bortezomib; Cytarabine; Daunorubicin Hydrochloride; Etoposide; Laboratory Biomarker Analysis; Mitoxantrone Hydrochloride; Pharmacological Study; Quality-of-Life Assessment; Questionnaire Administration; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07-06
    Completion
    2026-03-31
    Enrolment
    1,645

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm; Myeloid Sarcoma
    InterventionAsparaginase; Bortezomib; Cytarabine; Daunorubicin Hydrochloride +7 more
    PhasePhase 3
    Registry statusCompleted

  • Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    NCT01223027 · start 2011-03

    Registered record
    Registry ID
    NCT01223027
    Conditions
    Metastatic Renal Cell Carcinoma
    Interventions
    Dovitinib; Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2014-06
    Enrolment
    564

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Renal Cell Carcinoma
    InterventionDovitinib; Sorafenib
    PhasePhase 3
    Registry statusCompleted

  • Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

    NCT01258608 · start 2011-02-08

    Registered record
    Registry ID
    NCT01258608
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Mapatumumab; Placebo; Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-02-08
    Completion
    2017-11-29
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionMapatumumab; Placebo; Sorafenib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

    NCT01222676 · start 2010-10

    Registered record
    Registry ID
    NCT01222676
    Conditions
    Bladder Cancer
    Interventions
    cisplatin; gemcitabine hydrochloride; sorafenib tosylate; imaging biomarker analysis; laboratory biomarker analysis; computed tomography; neoadjuvant therapy; fludeoxyglucose F 18
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    Interventioncisplatin; gemcitabine hydrochloride; sorafenib tosylate; imaging biomarker analysis +4 more
    PhasePhase 2
    Registry statusUnknown